Evidence map›Paper›PMID 30233365›Full record

ArticleFrontiers in pharmacology2018

Behavioral Effects of a Potential Novel TAAR1 Antagonist.

Vincent M Lam, Catharine A Mielnik, Corey Baimel, Pieter Beerepoot, Stefano Espinoza, Ilya Sukhanov, Wendy Horsfall, Raul R Gainetdinov, Stephanie L Borgland, Amy J Ramsey and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. eLife · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Vincent M LamDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Catharine A MielnikDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Corey BaimelDepartment of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
Pieter BeerepootDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Stefano EspinozaDepartment of Neuroscience and Brain Technologies, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Ilya SukhanovDepartment of Neuroscience and Brain Technologies, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Wendy HorsfallDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Raul R GainetdinovInstitute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russia.
Stephanie L BorglandDepartment of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
Amy J RamseyDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Ali SalahpourDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
University of Toronto · CAItalian Institute of Technology · ITUniversity of Calgary · CAHarvard University · USSt Petersburg University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The trace amine associated receptor 1 (TAAR1) is a G-protein coupled receptor expressed in the monoaminergic regions of the brain, and represents a potential novel therapeutic target for the treatment of neurological disorders. While selective agonists for TAAR1 have been successfully identified, only one high affinity TAAR1 antagonist has been described thus far. We previously identified four potential low potency TAAR1 antagonists through an

Indexed as

amphetaminecocainedopamine transporter (DAT)electrophysiologylocomotor activityTAAR1

Identifiers

PMID30233365
PMCPMC6131539
OpenAlexW2889009582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.